Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study - Publication - Bridge of Knowledge

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Abstract

Citations

7 9

CrossRef
0

Web of Science
7 3

Scopus

Authors (24)

Ajay Gopal
Stephen Schuster
Nathan Fowler
Judith Trotman
Georg Hess
Jing-Zhou Hou
Abdulraheem Yacoub
Michael Lill
Peter Martin
Umberto Vitolo
Andrew Spencer
John Radford
Wojciech Jurczak MD, PhD, Prof
James Morton
Dolores Caballero
Sanjay Deshpande
Gary Gartenberg
Shean-Sheng Wang
Rajendra Damle
Michael Schaffer
Sriram Balasubramanian
Jessica Vermeulen
Bruce Cheson
Gilles Salles

Cite as

Full text

full text is not available in portal

full content of the article see on external site open in new tab

Details

Category:: Magazine publication
Type:: Magazine publication
Published in:: JOURNAL OF CLINICAL ONCOLOGY no. 36, edition 23, pages 2405 - 2412,
ISSN: 0732-183X
ISSN:: 0732-183X
Publication year:: 2018
DOI:: Digital Object Identifier (open in new tab) 10.1200/jco.2017.76.8853
Verified by:: No verification

seen 95 times